Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640809 · ClinicalTrials.gov registry record · Phase 4
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 408
- Enrollment target
NCT00640809 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 408 participants.
The verdict
NCT00640809, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 408 participants
- Enrollment target
Study Summary
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
Interventions
- OTHER Placebo
- DRUG Celecoxib
- DRUG Ibuprofen plus Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640809
The ClinicalTrials.gov registry entry for NCT00640809 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00640809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640809 about?
NCT00640809 is a clinical study titled "Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole". To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
What is the current status of trial NCT00640809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 408 participants. The study started on 2003-10. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00640809?
The interventions under investigation include: Placebo (OTHER), Celecoxib (DRUG), Ibuprofen plus Omeprazole (DRUG).
Who is sponsoring clinical trial NCT00640809?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.